CALIFORNIA: Tobacco smoking is the leading cause of avoidable death in the US, and chronic exposure to tobacco smoke is related to increased incidences of cancer as well as vascular disease, according to the United States Center for Disease Control. Many substitutes have been created to help individuals quit smoking cigarettes, such as herbal cigarettes, e-cigs, vaping, specialized gum, and many other ways.
Studies found in The Washington Post, pulmonologist Dr. Donald Tashkin, Professor Emeritus at the David Geffen School of Medicine at UCLA, has assumed that there would be a positive association between marijuana use and lung cancer, and that the association would be more positive with heavier use. What they found instead was no connection at all, and even a suggestion of some protective effect.
CV Sciences is currently in development of Cannabidiol-based potential U.S. Food and Drug Administration approved drugs. The company’s pipeline is the CVSI-007, a chewing gum that contains nicotine and synthetic Cannabidiol to support cessation of smokeless tobacco use and addiction. CV Sciences currently has two distinct operations: the Pharmaceuticals and Consumer Products Divisions. These divisions are supported by its medical and scientific advisory board, and advanced art production facilities.